Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Solasia Pharma K.K. is a Japan-based biopharmaceutical company focused on developing and commercializing innovative drugs for oncology and other therapeutic areas. Its key products include the anti-cancer drug, DaxibotulinumtoxinA, and the anti-cancer agent, SP-01, which target specific patient populations in Japan and Asia, leveraging its strong regulatory relationships in these markets.
Solasia generates revenue primarily through the sale of its proprietary oncology drugs, which are priced at a premium due to their unique formulations and targeted applications. Its competitive advantage lies in its strong pipeline of products tailored for the Asian market, where it has established partnerships with local distributors to enhance market penetration.
Regulatory approvals for new drugs in Japan and Asia
Partnership announcements with larger pharmaceutical companies
Clinical trial results for pipeline products
Market adoption rates of existing drugs
Regulatory changes in drug approval processes in key markets
Technological advancements in oncology treatments that could render current products obsolete
Emergence of generic alternatives for its proprietary drugs
Increased competition from larger pharmaceutical companies with more resources
Negative operating cash flow impacting liquidity
Potential reliance on equity financing for future R&D investments
moderate - The demand for pharmaceuticals is somewhat insulated from economic cycles; however, economic downturns can affect healthcare spending.
Low - As a low-debt company, rising interest rates have minimal impact on financing costs, but they could affect overall market sentiment and valuations.
minimal - The company has a low debt-to-equity ratio of 0.05, indicating limited reliance on external financing.
growth - Investors looking for high-growth opportunities in the biotech sector will find Solasia appealing due to its innovative drug pipeline.
high - The stock has exhibited significant volatility, reflected in a 1-year return of -25.8%.
